In contrast, insertions in exon 20 of EGFR, which account for roughly 1–10% of all EGFR mutations, are associated with a reduced efficacy of tyrosine kinase inhibitors (TKIs) and represent the third most common type of EGFR mutation in NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.